A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Subcutaneous Epoetin Alfa or Beta to Maintenance Treatment With Subcutaneous RO0503821 in Dialysis Patients With Chronic Renal Anemia

This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Inclusion Criteria:

• adult patients >=18 years of age;
• chronic renal anemia;
• on dialysis (hemodialysis or peritoneal dialysis) therapy for at least 3 months;
• receiving sc epoetin alfa or beta for at least 3 months prior to the run-in period.

Exclusion Criteria:

• women who are pregnant, breastfeeding or using unreliable birth control methods;
• use of any investigational drug within 30 days preceding the run-in phase, or during the run-in or study treatment period.